Literature DB >> 18398058

Dasatinib suppresses in vitro natural killer cell cytotoxicity.

Stephen J Blake, A Bruce Lyons, Cara K Fraser, John D Hayball, Timothy P Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18398058     DOI： 10.1182/blood-2008-02-138701

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  30 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

2.  A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.

Authors:  John J Powers; Jason A Dubovsky; P K Epling-Burnette; Lynn Moscinski; Ling Zhang; Satu Mustjoki; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2011-01-27

3.  Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.

Authors:  Roberto Bellucci; Hong-Nam Nguyen; Allison Martin; Stefan Heinrichs; Anna C Schinzel; William C Hahn; Jerome Ritz
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

4.  Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Authors:  Sara Ali; Ruhena Sergeant; Stephen G O'Brien; Letizia Foroni; Corinne Hedgley; Gareth Gerrard; Dragana Milojkovic; Kate Stringaris; Ahmad Khoder; Abdullah Alsuliman; Maria Gilleece; Ian H Gabriel; Nichola Cooper; John M Goldman; Jane F Apperley; Richard E Clark; David Marin; Katayoun Rezvani
Journal:  Blood       Date:  2012-07-19       Impact factor: 22.113

5.  Genomic Analysis of Kidney Allograft Injury Identifies Hematopoietic Cell Kinase as a Key Driver of Renal Fibrosis.

Authors:  Chengguo Wei; Li Li; Madhav C Menon; Weijia Zhang; Jia Fu; Brian Kidd; Karen L Keung; Christopher Woytovich; Ilana Greene; Wenzhen Xiao; Fadi Salem; Zhengzi Yi; John Cijiang He; Joel T Dudley; Barbara Murphy
Journal:  J Am Soc Nephrol       Date:  2016-12-07       Impact factor: 10.121

Review 6.  Large granular lymphocytosis during dasatinib therapy.

Authors:  Zhi-Yuan Qiu; Wei Xu; Jian-Yong Li
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

7.  Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.

Authors:  Charles Chuah; Junia V Melo
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

8.  Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.

Authors:  Takashi Kumagai; Eri Matsuki; Koiti Inokuchi; Kazuteru Ohashi; Atsushi Shinagawa; Jin Takeuchi; Chikashi Yoshida; Shinichiro Okamoto; Hisashi Wakita; Yasuji Kozai; Yukari Shirasugi; Shin Fujisawa; Osamu Iwase; Shingo Yano; Kaichi Nishiwaki; Koji Oba; Junichi Sakamoto; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2013-12-03       Impact factor: 2.490

9.  Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

Authors:  K Ishiyama; T Kitawaki; N Sugimoto; T Sozu; N Anzai; M Okada; M Nohgawa; K Hatanaka; N Arima; T Ishikawa; S Tabata; T Onaka; S Oka; Y Nakabo; R Amakawa; M Matsui; T Moriguchi; A Takaori-Kondo; N Kadowaki
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

10.  Requirement and redundancy of the Src family kinases Fyn and Lyn in perforin-dependent killing of Cryptococcus neoformans by NK cells.

Authors:  Paul Oykhman; Martina Timm-McCann; Richard F Xiang; Anowara Islam; Shu Shun Li; Danuta Stack; Shaunna M Huston; Ling Ling Ma; Christopher H Mody
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.